Many generic <a target="_blank" rel="noopener noreferrer" href="https://www.vectorconsulting.in/en/industries/life-sciences/">pharma companies</a> continue to struggle with high rates of invalid OOS and lab incidents, leaving them vulnerable to adverse observations from the US FDA. Many have stagnated because the real reason behind the so-called ‘analyst errors’ was misdiagnosed. This article provides a systemic analysis of the real reasons behind invalid OOS and suggests ways to drastically reduce Quality Management System (QMS) events in the lab. Despite years of dedicated efforts by Indian pharmaceutical companies to uphold FDA compliance, they continue to face numerous challenges, including receiving observations, warning letters, and, in some cases, drug recall mandates from the US FDA. For a typical large pharmaceutical firm, 40%-60% of these issues are attributed to Good Laboratory Practice (GLP) violations.<figure class="image"><img style="aspect-ratio:4000/2227;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-25_1758900668.jpg" width="4000" height="2227"></figure>When a company receives a warning letter, the FDA makes it clear that the company must correct the problem and provide directions and a time frame for the company to inform the FDA of their plans for correction. Failure to address the FDA's concerns can lead to enforcement actions with significant repercussions, as well as product liability exposure. Therefore, when a warning letter is received, company employees, especially senior management (already very busy), scramble to address it in the stipulated time frame. It is estimated that a single warning letter to a pharma lab within a company can result in a loss of up to 900 man-hours across the hierarchy. This increases exponentially when multiple warning letters are received simultaneously. It has to be noted that this will be at the cost of progress on their routine, ongoing tasks.<figure class="image"><img style="aspect-ratio:4000/1882;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-26_1758900781.jpg" width="4000" height="1882"></figure>After this marathon, the remediation procedures that the FDA expects companies to implement can be even more expensive than complying in the first place. Moreover, there are long-term repercussions in terms of loss of credibility with regulators - not just the FDA but also other global regulators, leading to increased scrutiny and more inspections. In cases of repeat offenders, they often have to pay hefty fines and sign a consent decree or permanent injunction that will bind them to comply in perpetuity. All this can impact the company’s business/financial performance, affect company valuations, and reduce the overall reputation. <h2>The problem</h2>The major reasons for FDA warning letters are not unknown. About 50% of FDA warning letters pinpoint CAPA failures.(2) CAPA failures also show up year after year in these warning letters. Most of these CAPA failures are also clearly indicated by the FDA as failures of root cause analysis.<figure class="image"><img style="aspect-ratio:16668/8279;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//ls-article-1-img-3-01-1733242664_1776775147.jpg" width="16668" height="8279"></figure><h2>What does not work well?</h2>So, over the years, pharma labs have been using multiple techniques to identify the root causes, enabling them to take action to improve their quality performance. The popular techniques employed include 5 Whys, Fishbone diagrams, Pareto charts, Failure Mode and Effects Analysis (FMEA), Decision Trees, and Brainstorming. A significant chunk of the results of these analyses point to human or analyst error (about 44%). Therefore, some of the typical actions companies have taken include adopting digital systems for reduce documentation errors, automating a few quality processes, increasing supervision in the lab, increasing analyst training, and adding resources to reduce the load on the system.<figure class="image"><img style="aspect-ratio:4000/3149;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-27_1758902019.jpg" width="4000" height="3149"></figure>However, experience has shown that many of these companies that these steps, while offering some improvement, do not consistently help sustain high-quality standards. After a while, any improvement that is accrued stagnates or, even more perplexingly, when something improves, something else seems to deteriorate.<figure class="image"><img style="aspect-ratio:4000/1969;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-28_1758902073.jpg" width="4000" height="1969"></figure>Moreover, the FDA has increasingly been criticising the finding of ‘human error’ as the conclusion of root cause analysis, calling it limited or shallow, and has been urging companies to take a deeper look.<figure class="image"><img style="aspect-ratio:4000/2755;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-29_1760597729.jpg" width="4000" height="2755"></figure><h2>The real root cause: Cognitive overload</h2>A closer study of the testing environment in pharma companies indicates that analysts are often under a state of significant ‘cognitive overload’.The analysts have the responsibility to:<ul><li>Conduct all activities for assigned tests as per the TDS (Test Data Sheet) - i.e., collect the glassware and documents, arrange for chemicals and reagents, ensure the validity of all solutions prepared until tests are complete, select appropriate equipment (e.g., column), manage instruments, etc.   </li><li>Generate an audit trail, and they also have to record the equipment used.   </li><li>Concurrently record various observations in TDS and maintain a separate checklist to ensure no steps are missed.</li></ul><figure class="image"><img style="aspect-ratio:16668/6058;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//ls-article-1-img-6-01-1733242720_1776775310.jpg" width="16668" height="6058"></figure><figure class="image"><img style="aspect-ratio:4000/3278;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-30_1760597801.jpg" width="4000" height="3278"></figure>Skips and misses: The analysts have to manage all these in an eight-hour shift by switching between various stages of testing (instrument setting/monitoring, solution preparation, mobile phase, collecting glassware, checking/arranging resources, etc.) and by trying to take advantage of the natural waiting time in some of these stages. Unfortunately, the human brain finds such a balancing act and this level of multitasking very difficult to manage. Therefore, occurrences of inadvertent skips and misses become inevitable.<figure class="image"><img style="aspect-ratio:4000/3218;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-31_1760597817.jpg" width="4000" height="3218"></figure>Systemic error disguised as human error:In addition to such human errors, testing environments also tend to have systemic errors due to:<ul><li>Missing information in the SOPs set or due to inadequately documented SOPs.  </li><li>A process gap or a gap in the testing method.</li></ul> However, when faced with a daily melee of different kinds of problems, it is difficult for managers to correctly infer and assign real causality to these errors. So, in this confusion, even systemic errors are mistaken for human error and vice versa. This inevitably leads to frequent finger-pointing, stress and inability to take timely corrective actions.<figure class="image"><img style="aspect-ratio:4000/2742;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-32_1760597853.jpg" width="4000" height="2742"></figure><h2>Direction of solution</h2>Based on these insights, it is clear that the only option is to address the cognitive overload in the system first to reduce real manual errors to a minimum. Then the systemic errors due to incorrect methods, unclear procedures, etc., will become visible, and actions can be taken to rectify them. While this logic is unrefutably simple, implementing a system-wide, counterintuitive solution that can significantly reduce cognitive load on analysts without sacrificing overall productivity is obviously a huge challenge. The key is to release capacity by identifying and eliminating significant wastages in the analysts’ activities. Research by Vector has shown that the level of analyst capacity wastage can be as high as 40% in a typical pharma lab.<figure class="image"><img style="aspect-ratio:4000/5116;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-461psd_1760597899.jpg" width="4000" height="5116"></figure>For instance, a significant chunk of time (nearly three hours of a single analyst’s working day) is wasted in just the multiple to-and-fro movements during the various activities of an analyst’s work, as illustrated in a time-and-motion study at a major pharmaceutical lab.<figure class="image"><img style="aspect-ratio:4000/2465;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-33_1760597987.jpg" width="4000" height="2465"></figure><h2>Conclusion</h2>The ‘flow’ solution that Vector implements to eliminate these wastages, and release capacity serves a dual purpose. On the one hand, it enables the released capacity to be used to control the analysts’ loading, and on the other, it resets the company’s quality practices to a much higher level of rigour. If companies can thus address cognitive overload, the true root cause of their quality issues, they can reduce quality-related inconsistencies and keep themselves inspection-ready at all times. With that, one is sure to see a dramatic dip in the warning letters the FDA has to issue. <h2>Case Study</h2>One of the largest generic drug manufacturers in the world was facing a slowdown in its new product approvals. The high frequency of OOS occurrences, especially invalid OOS cases and lab incidents, was raising doubts about the robustness of testing with the auditing agencies. Evidently, like everyone else in the industry, this company was also continuously trying to solve these issues and improve. However, after a while, any improvement from these new initiatives stalled. Thus, to achieve a sustainable jump in performance, the company, with the help of Vector, pioneered the implementation of a revolutionary new approach that had not been applied in the pharma industry. Within a few months, they could significantly reduce invalid OOS and bring down lab incidents!<figure class="image"><img style="aspect-ratio:4000/2948;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-34_1758902804.jpg" width="4000" height="2948"></figure>

BA Read More

Problem: Pharmaceutical companies are facing an increasing number of the United Stated Food and Drug Administration (US FDA) warning letters due to persistent Corrective and Preventive Action (CAPA) failures, mainly caused by inadequate root cause analysis. Most failures are attributed to human error (40%-55%). But deeper analysis reveals that cognitive overload among analysts is the real root cause. Constant multitasking leads to inadvertent skips and systemic errors, creating compliance risks. Solution: A structured, flow-focused approach should be implemented to eliminate wastage, reduce analyst workload, and enhance Standard Testing Procedures (STPs). By freeing up 40% of analyst capacity, cognitive overload errors can be minimised, making systemic gaps more visible and easier to correct. Benefits: This solution significantly reduces invalid Out of Specification (OOS), minimises lab incidents, and improves compliance. Companies adopting this approach stay inspection-ready and mitigate regulatory risks, ensuring sustained quality standards and fewer FDA observations.

Key Takeaways

Many generic pharma companies continue to struggle with high levels of invalid OOS and lab incidents, making them vulnerable to adverse observations from the US FDA. Often, 'analyst error' is cited as the reason, but the real reason is something else.

Getting to the true root of laboratory quality problems

Many generic <a target="_blank" rel="noopener noreferrer" href="https://www.vectorconsulting.in/en/industries/life-sciences/">pharma companies</a> continue to struggle with high rates of invalid OOS and lab incidents, leaving them vulnerable to adverse observations from the US FDA. Many have stagnated because the real reason behind the so-called ‘analyst errors’ was misdiagnosed. This article provides a systemic analysis of the real reasons behind invalid OOS and suggests ways to drastically reduce Quality Management System (QMS) events in the lab. Despite years of dedicated efforts by Indian pharmaceutical companies to uphold FDA compliance, they continue to face numerous challenges, including receiving observations, warning letters, and, in some cases, drug recall mandates from the US FDA. For a typical large pharmaceutical firm, 40%-60% of these issues are attributed to Good Laboratory Practice (GLP) violations.<figure class="image"><img style="aspect-ratio:4000/2381;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image_1766649963.png" alt="Vector Consulting Group | Article | Lab Quality | FDA actions against Indian drug companies including OAI warning letters and recalls from 2015 to 2024." width="4000" height="2381"></figure>When a company receives a warning letter, the FDA makes it clear that the company must correct the problem and provide directions and a time frame for the company to inform the FDA of their plans for correction. Failure to address the FDA's concerns can lead to enforcement actions with significant repercussions, as well as product liability exposure. Therefore, when a warning letter is received, company employees, especially senior management (already very busy), scramble to address it in the stipulated time frame. It is estimated that a single warning letter to a pharma lab within a company can result in a loss of up to 900 man-hours across the hierarchy. This increases exponentially when multiple warning letters are received simultaneously. It has to be noted that this will be at the cost of progress on their routine, ongoing tasks.  <figure class="image"><img style="aspect-ratio:4000/1882;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-26_1758900781.jpg" alt="Vector Consulting Group | Article | Lab Quality | Infographic showing estimated 900 man-hours required to respond to a single FDA warning letter over 15 days involving 15 people." width="4000" height="1882"></figure>After this marathon, the remediation procedures that the FDA expects companies to implement can be even more expensive than complying in the first place. Moreover, there are long-term repercussions in terms of loss of credibility with regulators - not just the FDA but also other global regulators, leading to increased scrutiny and more inspections. In cases of repeat offenders, they often have to pay hefty fines and sign a consent decree or permanent injunction that will bind them to comply in perpetuity. All this can impact the company’s business/financial performance, affect company valuations, and reduce the overall reputation. <h2>The problem</h2>The major reasons for FDA warning letters are not unknown. About 50% of FDA warning letters pinpoint CAPA failures.(2) CAPA failures also show up year after year in these warning letters. Most of these CAPA failures are also clearly indicated by the FDA as failures of root cause analysis.<figure class="image"><img style="aspect-ratio:16668/8279;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//ls-article-1-img-3-01-1733242664_1776775109.jpg" alt="Vector Consulting Group | Article | Lab Quality | Excerpts of typical FDA warning letter comments on root cause analysis failures." width="16668" height="8279"></figure><h2>What does not work well?</h2>So, over the years, pharma labs have been using multiple techniques to identify the root causes, enabling them to take action to improve their quality performance. The popular techniques employed include 5 Whys, Fishbone diagrams, Pareto charts, Failure Mode and Effects Analysis (FMEA), Decision Trees, and Brainstorming. A significant chunk of the results of these analyses point to human or analyst error (about 44%). Therefore, some of the typical actions companies have taken include adopting digital systems for reduce documentation errors, automating a few quality processes, increasing supervision in the lab, increasing analyst training, and adding resources to reduce the load on the system.<figure class="image"><img style="aspect-ratio:4000/3149;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-27_1758902019.jpg" alt="Vector Consulting Group | Article | Lab Quality | Pie chart showing that traditional root cause analysis techniques attribute approximately 44% of lab quality failures to human or analyst error." width="4000" height="3149"></figure>However, experience has shown that many of these companies that these steps, while offering some improvement, do not consistently help sustain high-quality standards. After a while, any improvement that is accrued stagnates or, even more perplexingly, when something improves, something else seems to deteriorate.<figure class="image"><img style="aspect-ratio:4000/1969;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-28_1758902073.jpg" alt="Vector Consulting Group | Article | Lab Quality | Pharma quality control chart showing volatile monthly OOS metric trends versus targeted CAPA performance goals." width="4000" height="1969"></figure>Moreover, the FDA has increasingly been criticising the finding of ‘human error’ as the conclusion of root cause analysis, calling it limited or shallow, and has been urging companies to take a deeper look.<figure class="image"><img style="aspect-ratio:4000/2752;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image_1767276465.png" alt="Vector Consulting Group | Article | Lab Quality | FDA observations identifying human error as root cause of violations in investigations testing and CAPA processes." width="4000" height="2752"></figure><h2>The real root cause: Cognitive overload</h2>A closer study of the testing environment in pharma companies indicates that analysts are often under a state of significant ‘cognitive overload’.The analysts have the responsibility to:<ul><li>Conduct all activities for assigned tests as per the TDS (Test Data Sheet) - i.e., collect the glassware and documents, arrange for chemicals and reagents, ensure the validity of all solutions prepared until tests are complete, select appropriate equipment (e.g., column), manage instruments, etc.    </li><li>Generate an audit trail, and they also have to record the equipment used.    </li><li>Concurrently record various observations in TDS and maintain a separate checklist to ensure no steps are missed.  </li></ul><figure class="image"><img style="aspect-ratio:16668/6058;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//ls-article-1-img-6-01-1733242720_1776775286.jpg" alt="Vector Consulting Group | Article | Lab Quality | Definition of cognitive overload caused by excessive information and multiple simultaneous tasks." width="16668" height="6058"></figure><figure class="image"><img style="aspect-ratio:4000/3278;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-30_1760597801.jpg" alt="Vector Consulting Group | Article | Lab Quality | Timeline chart showing how overlapping tasks like HPLC machine preparation, weighing, and sample preparation cause analyst overtime in a typical pharma lab." width="4000" height="3278"></figure>Skips and misses: The analysts have to manage all these in an eight-hour shift by switching between various stages of testing (instrument setting/monitoring, solution preparation, mobile phase, collecting glassware, checking/arranging resources, etc.) and by trying to take advantage of the natural waiting time in some of these stages. Unfortunately, the human brain finds such a balancing act and this level of multitasking very difficult to manage. Therefore, occurrences of inadvertent skips and misses become inevitable.<figure class="image"><img style="aspect-ratio:4000/3218;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-31_1760597817.jpg" alt="Vector Consulting Group | Article | Lab Quality | Mind map diagram detailing the simultaneous tasks of a pharma lab analyst, including sample preparation, HPLC report collection, water collection, and documentation" width="4000" height="3218"></figure>Systemic error disguised as human error:In addition to such human errors, testing environments also tend to have systemic errors due to:<ul><li>Missing information in the SOPs set or due to inadequately documented SOPs.   </li><li>A process gap or a gap in the testing method.</li></ul> However, when faced with a daily melee of different kinds of problems, it is difficult for managers to correctly infer and assign real causality to these errors. So, in this confusion, even systemic errors are mistaken for human error and vice versa. This inevitably leads to frequent finger-pointing, stress and inability to take timely corrective actions.<figure class="image"><img style="aspect-ratio:4000/2742;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-32_1760597853.jpg" alt="Vector Consulting Group | Article | Lab Quality | Pharma root cause analysis of errors, chart differentiating between SOP execution errors and systemic documentation gaps." width="4000" height="2742"></figure><h2>Direction of solution</h2>Based on these insights, it is clear that the only option is to address the cognitive overload in the system first to reduce real manual errors to a minimum. Then the systemic errors due to incorrect methods, unclear procedures, etc., will become visible, and actions can be taken to rectify them. While this logic is unrefutably simple, implementing a system-wide, counterintuitive solution that can significantly reduce cognitive load on analysts without sacrificing overall productivity is obviously a huge challenge. The key is to release capacity by identifying and eliminating significant wastages in the analysts’ activities. Research by Vector has shown that the level of analyst capacity wastage can be as high as 40% in a typical pharma lab.<figure class="image"><img style="aspect-ratio:4000/5119;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image_1767276516.png" alt="Vector Consulting Group | Article | Lab Quality | Pie chart illustrating that 40 percent of a lab analyst's time is lost to operational wastage and inefficiencies, leaving only 60 percent as productive time." width="4000" height="5119"></figure>For instance, a significant chunk of time (nearly three hours of a single analyst’s working day) is wasted in just the multiple to-and-fro movements during the various activities of an analyst’s work, as illustrated in a time-and-motion study at a major pharmaceutical lab.<figure class="image"><img style="aspect-ratio:4000/2465;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-33_1760597987.jpg" alt="Vector Consulting Group | Article | Lab Quality | Movement of a single analyst across multiple workstations during a workday." width="4000" height="2465"></figure><h2>Conclusion</h2>The ‘flow’ solution that Vector implements to eliminate these wastages, and release capacity serves a dual purpose. On the one hand, it enables the released capacity to be used to control the analysts’ loading, and on the other, it resets the company’s quality practices to a much higher level of rigour. If companies can thus address cognitive overload, the true root cause of their quality issues, they can reduce quality-related inconsistencies and keep themselves inspection-ready at all times. With that, one is sure to see a dramatic dip in the warning letters the FDA has to issue. <h2>Case Study</h2>One of the largest generic drug manufacturers in the world was facing a slowdown in its new product approvals. The high frequency of OOS occurrences, especially invalid OOS cases and lab incidents, was raising doubts about the robustness of testing with the auditing agencies. Evidently, like everyone else in the industry, this company was also continuously trying to solve these issues and improve. However, after a while, any improvement from these new initiatives stalled. Thus, to achieve a sustainable jump in performance, the company, with the help of Vector, pioneered the implementation of a revolutionary new approach that had not been applied in the pharma industry. Within a few months, they could significantly reduce invalid OOS and bring down lab incidents!<figure class="image"><img style="aspect-ratio:4000/2948;" src="https://web-assets.vectorconsulting.in/storage/editor_uploads//image-34_1758902804.jpg" alt="Vector Consulting Group | Article | Lab Quality | Key metrics showing reduction in pharmaceutical lab invalid OOS cases and decreased analyst fatigue." width="4000" height="2948"></figure>

Download PDF

Discover how addressing the root cause of analyst overload reduces invalid OOS and lab errors in pharma QC. Prevent FDA warnings and read the full article.